Bristol’s Dolan Advocates Fixed-Term Exclusivity As Plavix Faces Challenge
Executive Summary
Bristol-Myers Squibb is approaching future patent applications with an eye toward early intellectual property challenges, CEO Peter Dolan stated during a Jan. 25 year-end earnings presentation
You may also be interested in...
Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?
As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development
Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?
As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development
Drugs Should Get Longer Patents In Exchange For More Safety Data – Wood
Offering extended exclusivity, in advance, for drugs that address an unmet medical need could bring a necessary boost to research and development efforts, Vanderbilt University's Alastair Wood said